ſ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287				
Estimated average burden					
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					013	Section St		ivestine		inpany Act of	1940										
1. Name and Address of Reporting Person [*] SCHOEMAKER KATHLEEN K					2. Issuer Name and Ticker or Trading Symbol TANDEM DIABETES CARE INC [TNDM] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officier (aive title Other (carocify)												wner				
(Last) (First) (Middle) C/O DOMAIN ASSOCIATES, LLC ONE PALMER SQUARE						3. Date of Earliest Transaction (Month/Day/Year) Officer (give title below) Other (specify below) 11/19/2013 Delow Delow															
(Street) PRINCETON NJ 08542					4. If Amendment, Date of Original Filed (Month/Day/Year)								 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 								
(City)	(State)	(Zip)																		
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transa Date (Month/D)			action 2A. Deemed Execution Date,			guired, Disposed of, or Benefici 3. Transaction Code (Instr. 8)				A) or	5. Amount of Securities Beneficially Owned Following			Direct Ir Indirect B C.4) C	7. Nature of Indirect Beneficial Ownership						
							Code	v	Amount	(A) or (D)	Price	Reported Transaction (Instr. 3 and	(s) 4)			Instr. 4)					
Common Stock			11/19	9/2013		С		3,189,05	3,189,058 A		3,189,0)58	I I		By Domain Partners VII, L.P.						
Common Stock			11/19/	9/2013		С		54,390	Α	(1)	54,390		I		By DP VII Associates, L.P.						
			Table II -							osed of, c onvertibl			wned								
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	xercise (Month/Day/Year) e of vative	3A. Deemed Execution Date, if any (Month/Day/Year	Code		5. Number of Derivative		6. Date Exercisa Expiration Date (Month/Day/Year		ate	ble and 7. Title and A Securities Un		f 8. Price of Derivative Security (Instr. 5)	derivat Securi Benefi Ownec Follow	tive ties cially I ing	10. Ownershi Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownershi t (Instr. 4)				
				Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amount or Number of Shares		Report Transa (Instr.	ction(s)						
Series B Preferred Stock	(1)	11/19/2013		С			356,111	(1)		(1)		(1)		(1) (1)		356,111	\$0		0 I		By Domain Partners VII, L.P.
Series C Preferred Stock	(1)	11/19/2013		с			549,833	(1)		(1)		(1) (1)		Common Stock	549,833	\$0		0 I		By Domain Partners VII, L.P.	
Series D Preferred Stock	(1)	11/19/2013		С			2,283,114	(1)		(1)	Common Stock	2,283,11	4 \$0	\$0 0		I	By Domain Partners VII, L.P.				
Warrant to Purchase Series D Preferred Stock	\$4.4	11/19/2013		J ⁽²⁾			590,403	(3)	(3)	Series D Preferred Stock	590,403	3 \$0		0	I	By Domain Partners VII, L.P.				
Warrant to Purchase Common Stock	\$7.37	11/19/2013		J ⁽²⁾		352,351		(4)	(4)	Common Stock	352,351	1 \$0	352	2,351	I	By Domain Partners VII, L.P.				
Series B Preferred Stock	(1)	11/19/2013		С			6,071	(1)	(1)	Common Stock	6,071	\$0		0	I	By DP VII Associates L.P.				
Series C Preferred Stock	(1)	11/19/2013		С			9,378	(1)	(1)	Common Stock	9,378	\$0		0	I	By DP VII Associates L.P.				
Series D Preferred Stock	(1)	11/19/2013		с			38,941	(1)	(1)	Common Stock	38,941	\$0		0	I	By DP VII Associates L.P.				
Warrant to Purchase Series D Preferred Stock	\$4.4	11/19/2013		J (2)			10,068	(5)	(5)	Series D Preferred Stock	10,068	\$0		0 I		By DP VII Associates L.P.				
Warrant to Purchase	I		I											1							

Explanation of Responses:

Stock

1. All outstanding shares of the Issuer's preferred stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The preferred stock had no expiration date. The Common Stock equivalents of the preferred stock reflect the 1 for 1.6756 reverse split of the Common Stock effected in November 2013.

2. Upon the closing of the IPO the Warrants to purchase Series D Preferred Stock automatically converted into Warrants to purchase the number of shares of Common Stock that the Series D Preferred Stock underlying the

Warrants were convertible into, subject to the reverse split described in footnote (1), and the exercise price accordingly adjusted to \$7.37 per share.

3. The Warrant to purchase Series D Preferred Stock was immediately exercisable and expired as follows: 362,965 shares on 8/17/21; 90,741 shares on 5/25/22; and 136,697 shares on 7/17/22.

4. The Warrant to purchase Common Stock is immediately exercisable and expires as follows: 216,617 shares on 8/17/21; 54,154 shares on 5/25/22; and 81,580 shares on 7/17/22.

5. The Warrant to purchase Series D Preferred Stock was immediately exercisable and expired as follows: 6,190 shares on 8/17/21; 1,547 shares on 5/25/22; and 2,331 shares on 7/17/22.

6. The Warrant to purchase Common Stock is immediately exercisable and expires as follows: 3,694 shares on 8/17/21; 923 shares on 5/25/22; and 1,391 shares on 7/17/22.

Remarks:

/s/Kathleen K. Schoemaker

** Signature of Reporting Person

<u>11/19/2013</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.